Navigation Links
QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
Date:6/9/2008

VANCOUVER, June 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc., its wholly-owned subsidiary, has entered into an asset purchase agreement with Allergan Sales, LLC, a wholly-owned subsidiary of Allergan, Inc. (NYSE: AGN) to fully divest QLT's worldwide rights to Aczone(R), a prescription topical medicine approved in the United States and Canada for the treatment of acne vulgaris. Under the terms of the agreement, QLT will receive a one-time cash payment of approximately US$150 million upon closing, which is expected to occur in the third quarter of 2008.

"The divestment of Aczone is a major milestone for QLT and this transaction demonstrates that our persistence in completing the work needed to remove the blood monitoring restriction from the Aczone label in the United States provided significant value for our shareholders," said Bob Butchofsky, President and Chief Executive Officer of QLT. "This transaction is the second in a series of planned asset sales that, once completed, we expect will enable us to return meaningful proceeds to our shareholders."

The transaction has been approved by the Board of Directors of both QLT and Allergan, respectively. Closing of the transaction is subject to antitrust clearance under the Hart-Scott-Rodino Act and other customary closing conditions. Goldman, Sachs & Co. is acting as financial advisor to QLT in connection with the transaction.

The Aczone asset purchase agreement is the second agreement entered into by the Company to divest non-core assets since it announced its strategic restructuring earlier this year. Other assets offered for sale from QLT USA include Eligard(R) and the Atrigel(R) drug delivery system. On May 15, QLT anno
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Texas (PRWEB) July 25, 2014 Yisrayl Hawkins, ... Texas, is once again stirring the pot by revealing to ... they are deceived into worshipping Satan, the devil, in his ... clever plan organized by Satan, and carried out by the ... of the Creator from the Inspired Holy Scriptures and replacing ...
(Date:7/25/2014)... 2014 According to the Liver ... by Vkool.com, this is a comprehensive guide that ... and safe remedies for liver cirrhosis . ...     Chapter 1: Liver Cirrhosis Bible ... Learn About Liver Basics ,     Chapter 3: ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
(Date:7/24/2014)... nighttime production of the hormone melatonin, renders breast cancer ... drug, says a new study by Tulane University School ... Disruption by Exposure to Light at Night Drives Intrinsic ... the journal Cancer Research , is the first ... of tamoxifen in treating breast cancer. , , Principal ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, ... sub-segments with an in-depth analysis and forecasting of ... for this market with insights on trends, opportunities, ... and 36 figures spread through 157 pages and ... at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4
... Therapy for Cardiovascular Disease (IC3D) is a three-day ... cell-based therapies for treating cardiovascular diseases. The theme ... Building Blocks: Strategies for Cardiovascular Reconstruction in 2009." ... present basic, core discussions on stem cell science ...
... our troops" is no longer just,a slogan -- it,s ... and a,new marketing campaign for the renamed Bob ... JWT Atlanta., By focusing on the physical and ... and raising money to provide,resources and support for injured ...
... for Invisicare Is Put In Place, LAS ... SKVI), the developers of Invisicare, a patented polymer,delivery ... appointment of Geert Cauwenbergh, PhD to head its ... to expand the demand,for Invisicare in international markets. ...
... HOUSTON, Nov. 6 US Oncology, Inc. ("US Oncology" ... services companies,reported revenue of $821.7 million, EBITDA of $54.5 ... million and operating cash flow,of $35.1 million for the ... ended September 30, 2008, US Oncology reported revenue of ...
... MOUNT LAUREL, N.J., Nov. 6 At ... Inc. (Nasdaq: MEDQ ) is introducing ... top-ranked,interactive front-end speech recognition application, and RadWorkFlow(R), ... RadWorkFlow offers an efficient, simplified, and ...
... LIMS System Chosen by Hospital to Replace ... Global Med Technologies(R),Inc. ("Global Med" or ... e-Health, medical information technology company, today,announced that ... Laboratory,Information Management Software (marketed as "Labo Serveur" ...
Cached Medicine News:Health News:5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 2Health News:Bob Woodruff Foundation and JWT Introduce Marketing Campaign and Unveil www.ReMIND.org 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:US Oncology Reports Third Quarter 2008 Results 2Health News:US Oncology Reports Third Quarter 2008 Results 3Health News:US Oncology Reports Third Quarter 2008 Results 4Health News:US Oncology Reports Third Quarter 2008 Results 5Health News:US Oncology Reports Third Quarter 2008 Results 6Health News:US Oncology Reports Third Quarter 2008 Results 7Health News:US Oncology Reports Third Quarter 2008 Results 8Health News:US Oncology Reports Third Quarter 2008 Results 9Health News:US Oncology Reports Third Quarter 2008 Results 10Health News:US Oncology Reports Third Quarter 2008 Results 11Health News:US Oncology Reports Third Quarter 2008 Results 12Health News:US Oncology Reports Third Quarter 2008 Results 13Health News:US Oncology Reports Third Quarter 2008 Results 14Health News:US Oncology Reports Third Quarter 2008 Results 15Health News:US Oncology Reports Third Quarter 2008 Results 16Health News:US Oncology Reports Third Quarter 2008 Results 17Health News:US Oncology Reports Third Quarter 2008 Results 18Health News:US Oncology Reports Third Quarter 2008 Results 19Health News:US Oncology Reports Third Quarter 2008 Results 20Health News:US Oncology Reports Third Quarter 2008 Results 21Health News:US Oncology Reports Third Quarter 2008 Results 22Health News:US Oncology Reports Third Quarter 2008 Results 23Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 2Health News:MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 2Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 3Health News:Global Med Technologies(R), Inc.'s Inlog Subsidiary Licenses Its Leading Laboratory Information System to Gabriel Martin Hospital of Saint-Paul de la Reunion 4
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... invivodata inc., the ... and services for global clinical research, today announced ... provide the EXAcerbations of Chronic pulmonary disease Tool ... is a Patient-Reported Outcome (PRO) measure for evaluating ...
... testing in humans watershed moment for unique malaria ... a move that highlights the strength of public-private ... company Sanaria Inc., with support from the PATH ... 1 clinical trial -- the first tests in ...
Cached Medicine Technology:invivodata Certified to Deliver EXACT in COPD Trials 2invivodata Certified to Deliver EXACT in COPD Trials 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... 200 ophthalmoscope, the world's ... ophthalmoscope. Heine's aspherical optical ... along with innovative design ... the Beta 200 the ...
... The Heine Beta 200S is ... with a combination of patented ... and a range of corrective ... dpt. in single diopter steps. ...
... The ophthalmoscope with superior aspherical optics. The ... means of the aspherical optical system avoids ... 200 allows you to view the whole ... even with a small pupil. Conventional ophthalmoscopes ...
Medicine Products: